Clinical Trials Logo

Systemic Lupus Erythematosus clinical trials

View clinical trials related to Systemic Lupus Erythematosus.

Filter by:

NCT ID: NCT04895696 Recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Start date: October 11, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.

NCT ID: NCT04877691 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

Tulip SC
Start date: June 8, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy

NCT ID: NCT04835883 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients

Start date: September 26, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, one-arm single-center phase Ⅱa study exploring the efficacy and safety of CS20AT04 (HLA-haplo Matched Allogenic Bone Marrow-Derived Stem Cells) in two subpopulation group of systemic lupus erythematosus patients - lupus nephritis and lupus cytopenia.

NCT ID: NCT04833465 Recruiting - Fibromyalgia Clinical Trials

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

Start date: July 16, 2021
Phase:
Study type: Observational

The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations. This would enable objective assessment of pain and treatment in these populations and enable a much more precise approach to treatment. Such an endpoint stands to significantly improve outcomes in these patients by eliminating the need for a trial-and-error approach to treatment. This is a single site observational study that aims to collect initial pilot data in three distinct patient groups. As this is observational, there is no randomization or blinding in the study. Patients will be followed for a period of one year after enrollment. Baseline measurements will be taken at the time of enrollment, and at each subsequent standard of care clinic visit as feasible, for a period of one year. As this is an observational study, there will be no change to the treatment for any patient due to research activities. The primary objective of this study is the characterization of the nociceptive index in three pediatric rheumatology populations. The secondary objective is the characterization of the nociceptive index in these populations in response to standard of care interventions. This is necessary to demonstrate the ability of this approach to serve as an endpoint of treatment effect.

NCT ID: NCT04751396 Recruiting - Clinical trials for Rheumatoid Arthritis

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

Start date: April 20, 2022
Phase:
Study type: Observational

This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.

NCT ID: NCT04747288 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Objective Measurement With TCM Pattern for AIDDES

Start date: February 1, 2021
Phase:
Study type: Observational

To explore the association with TCM pattern and TCM tongue diagnosis for Autoimmune disease and Dry eye syndrome.

NCT ID: NCT04648059 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Epigenetics in Lupus Nephritis

Epi_LN
Start date: December 1, 2020
Phase:
Study type: Observational

This is a translational study for the identification of epigenetic changes detectable in sera of patients suffering from Systemic Lupus erythematosus. The aim of the study is to analyze whether circulating DNA fragments are 1) different in patients with or without Lupus nephritis and 2) present and detectable in the circulation before the development of Lupus nephritis.

NCT ID: NCT04582136 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus

SIRIUS
Start date: March 4, 2021
Phase: Phase 2
Study type: Interventional

This is a multi-center, double-blinded, randomized, placebo-controlled, phase 2 study to evaluate the efficacy and safety of sirolimus administered in addition to standard therapy, in patients with active SLE disease.

NCT ID: NCT04532541 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Monogenic Lupus in Childhood Onset Systemic Lupus Erythematosus

Start date: November 25, 2020
Phase:
Study type: Observational

The purpose of this study is to unravel the proportion of monogenic lupus in children onset Systemic lupus erythematosus (SLE), and to find out the diagnostic strategy for early detection of monogenic lupus.

NCT ID: NCT04530461 Recruiting - Clinical trials for Rheumatoid Arthritis

Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases

Start date: June 1, 2020
Phase:
Study type: Observational

An observational study aiming to assess the serological profile of SARS-Cov2 patients with systemic diseases such as systemic lupus erythematosus, Sjogren syndrome, sarcoidosis, inflammatory myopathies, Behçet's disease, Rheumatoid arthritis and Spondyloarthritis